These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3422537)

  • 1. Prognostic implications of basophil differentiation in chronic myeloid leukemia.
    Denburg JA; Browman G
    Am J Hematol; 1988 Feb; 27(2):110-4. PubMed ID: 3422537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myeloid leukaemia: evidence for basophil differentiation and histamine synthesis from cultured peripheral blood cells.
    Denburg JA; Wilson WE; Goodacre R; Bienenstock J
    Br J Haematol; 1980 May; 45(1):13-21. PubMed ID: 6929704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basophil production in myeloproliferative disorders: increases during acute blastic transformation of chronic myeloid leukemia.
    Denburg JA; Wilson WE; Bienenstock J
    Blood; 1982 Jul; 60(1):113-20. PubMed ID: 6952947
    [No Abstract]   [Full Text] [Related]  

  • 4. [A case of CML blast crisis with numerous megakaryocyte and basophil colony formations].
    Kitano K; Sagara T; Koike S; Kawakami Y; Iijima Y; Kaji R; Imai S; Saitoo H; Furuta S; Ando O
    Rinsho Ketsueki; 1985 May; 26(5):750-5. PubMed ID: 3863972
    [No Abstract]   [Full Text] [Related]  

  • 5. A new leukemia cell line with Philadelphia chromosome characterized as basophil precursors.
    Kishi K
    Leuk Res; 1985; 9(3):381-90. PubMed ID: 3858609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition by retinoic acid of myeloid progenitors in chronic myeloid leukemia and myeloproliferative disease: increased sensitivity in blastic phase of chronic myeloid leukemia.
    Januszewicz E; Rabizadah E; Maimon Z; Zaizov R; Shaklai M
    Pathology; 1988 Jan; 20(1):1-6. PubMed ID: 3163796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual expression of lymphoid/basophil markers on single blast cells transformed from chronic myeloid leukemia.
    Kuriyama K; Tomonaga M; Yao E; Soda H; Nonaka H; Jinnai I; Matsuo T; Yoshida Y; Amenomori T; Ichimaru M
    Leuk Res; 1986; 10(8):1015-24. PubMed ID: 3462436
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7.
    Agis H; Krauth MT; Mosberger I; Müllauer L; Simonitsch-Klupp I; Schwartz LB; Printz D; Böhm A; Fritsch G; Horny HP; Valent P
    J Clin Pathol; 2006 Apr; 59(4):396-402. PubMed ID: 16461568
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Differential analysis of BM cell morphology, immunophenotypic, cytogenetic characters and prognosis between myeloblastic and lymphoblastic crisis of CML].
    Liu YL; Wang XN; Liu HS
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Jun; 22(3):629-33. PubMed ID: 24989266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH; Johnson JR; Pazdur R
    Clin Cancer Res; 2005 Jan; 11(1):12-9. PubMed ID: 15671523
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential response to stem cell factor and Flt3 ligand by the FAB subtype in acute myeloid leukemia clonogenic cells.
    Murohashi I; Yoshida K; Kishimoto K; Takahashi T; Wakao D; Jinnai I; Yagasaki F; Kawai N; Suzuki T; Matsuda A; Hirashima K; Bessho M
    J Interferon Cytokine Res; 2002 Mar; 22(3):335-41. PubMed ID: 12034041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diagnostic and prognostic value of new biochemical and immunohistochemical parameters in chronic myeloid leukemia.
    Valent P; Agis H; Sperr W; Sillaber C; Horny HP
    Leuk Lymphoma; 2008 Apr; 49(4):635-8. PubMed ID: 18398724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and survival outcomes in patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era: Cohort study of 477 patients.
    Jain P; Kantarjian HM; Ghorab A; Sasaki K; Jabbour EJ; Nogueras Gonzalez G; Kanagal-Shamanna R; Issa GC; Garcia-Manero G; Kc D; Dellasala S; Pierce S; Konopleva M; Wierda WG; Verstovsek S; Daver NG; Kadia TM; Borthakur G; O'Brien S; Estrov Z; Ravandi F; Cortes JE
    Cancer; 2017 Nov; 123(22):4391-4402. PubMed ID: 28743165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on interferon-alpha2a and CML.
    Steegmann JL; Odriozola J; Rodriguez-Salvanés F; Giraldo P; García-Laraña J; Ferro MT; Benítez E; Pérez-Pons C; Giralt M; Escribano L; Lavilla E; Miguel A; Areal C; Pérez-Encinas M; Abad A; Maldonado J; Massagué I; Fernández-Rañada JM
    Haematologica; 1999 Nov; 84(11):978-87. PubMed ID: 10553157
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transformation of chronic myelogenous leukemia: clinical, morphologic, and cytogenetic features.
    Muehleck SD; McKenna RW; Arthur DC; Parkin JL; Brunning RD
    Am J Clin Pathol; 1984 Jul; 82(1):1-14. PubMed ID: 6588747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An evaluation of the prognostic significance of antigen CD95(Fas/APO-1) expression on the cells of patients with a myelodysplastic syndrome, acute myeloid leukemia and chronic myeloleukemia].
    Polosukhina ER; Kuznetsov SV; Logcheva NP; Zabotina TN; Tenuta MR; Shirin AD; Kaletin GI; Turkina AG; Tsvetaeva NV; Shishkin IuV; Kadagidze ZG; Khoroshko ND; Volkova MA; Baryshnikov AIu
    Ter Arkh; 1998; 70(7):21-5. PubMed ID: 9742630
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blast crisis of chronic myelogenous leukemia. Morphologic and immunological features.
    Nemoto K; Honma K; Fukuda T; Ohnishi Y
    Acta Pathol Jpn; 1986 Oct; 36(10):1441-54. PubMed ID: 3541490
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An in vitro study of basophil production in chronic myeloproliferative disorders.
    Piacibello W; Camussi G; Aglietta M
    Exp Hematol; 1984 Nov; 12(10):759-62. PubMed ID: 6334609
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular detection of survivin expression, antiapoptotic gene, and other prognostic markers, how they are correlated and how it could be of prognostic value in chronic myeloid leukemia patient.
    Zhara M; Mourad H; Farouk G; Elbatch M; Ezzat S; Sami W
    Egypt J Immunol; 2007; 14(2):51-62. PubMed ID: 20306657
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Granulocyte-macrophage colony-stimulating factor modulation of the inhibitory effect of transforming growth factor-beta on normal and leukemic human hematopoietic progenitor cells.
    Cashman JD; Eaves AC; Eaves CJ
    Leukemia; 1992 Sep; 6(9):886-92. PubMed ID: 1518302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.